Characterization of psoriasis patients in special body areas: real-world evidence from the Chinese Psoriasis Standardized Diagnosis and Treatment Center

References

• Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet. 2021;397(10281):1301–1315. doi: 10.1016/S0140-6736(20)32549-6.
   PubMed Web of Science ®Google Scholar
• James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858. doi: 10.1016/S0140-6736(18)32279-7.
   PubMed Web of Science ®Google Scholar
• Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385. doi: 10.1038/jid.2012.339.
   PubMed Web of Science ®Google Scholar
• Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. doi: 10.1136/bmj.m1590.
   PubMed Web of Science ®Google Scholar
• Callis Duffin K, Mason MA, Gordon K, et al. Characterization of patients with psoriasis in challenging-to-treat body areas in the Corrona Psoriasis Registry. Dermatology. 2021;237(1):46–55. doi: 10.1159/000504841.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Talamonti M, Cioni A, et al. Efficacy of tildrakizumab for the treatment of difficult-to-Treat areas: scalp, nail, palmoplantar and genital psoriasis. J Clin Med. 2022;11(9):2631.
   PubMed Web of Science ®Google Scholar
• Psoriasis Standardized Diagnosis and Treatment Center and real-world big data collection platform project launched in Beijing; 2020 [cited 2021 Nov 23]. Available from: https://topic.echemi.com/a/psoriasis-standardized-diagnosis-and-treatment-center-and-real-world-big-data-collection-platform-project-launched-in-beijing_101215.html
   Google Scholar
• Yang Z, Han S, Wu P, et al. Modeling posttreatment prognosis of skin lesions in patients with psoriasis in China. JAMA Netw Open. 2023;6(4):e236795. doi: 10.1001/jamanetworkopen.2023.6795.
   PubMed Web of Science ®Google Scholar
• Wei L, Chen S, Zhang Z, et al. Prevalence of tobacco smoking and its association with disease severity among patients with psoriasis in China: a cross-sectional study. Front Med. 2022;9:883458. doi: 10.3389/fmed.2022.883458.
   Web of Science ®Google Scholar
• Yang Z, Yao X, Wang M, et al. Updates in psoriasis diagnosis and treatment status in China: results from the National Psoriasis Center Registry. Chin Med J. 2023;136(23):2874–2876.
   PubMed Web of Science ®Google Scholar
• Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China (2018 complete edition). Zhonghua Pifuke Zazhi. 2019;52(10):667–710.
   Google Scholar
• Langley RG, Feldman SR, Nyirady J, et al. The 5-point Investigator’s Global Assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015;26(1):23–31. doi: 10.3109/09546634.2013.865009.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi: 10.1111/j.1365-2230.1994.tb01167.x.
   PubMed Web of Science ®Google Scholar
• Zheng Q, Kuai L, Jiang W, et al. Clinical feature, lifestyle behavior and non-communicable diseases comorbidities among psoriasis patients in Shanghai: gender disparity analysis based on a cross-sectional study. Clin Cosmet Investig Dermatol. 2022;15:2751–2762. doi: 10.2147/CCID.S393697.
   PubMed Web of Science ®Google Scholar
• Egeberg A, See K, Garrelts A, et al. Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish Skin Cohort. BMC Dermatol. 2020;20(1):3. doi: 10.1186/s12895-020-00099-7.
   PubMed Web of Science ®Google Scholar
• Larsabal M, Ly S, Sbidian E, et al. GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis. Br J Dermatol. 2019;180(3):647–656. doi: 10.1111/bjd.17147.
   PubMed Web of Science ®Google Scholar
• Menter A, Bhutani T, Ehst B, et al. Narrative review of the emerging therapeutic role of brodalumab in difficult-to-treat psoriasis. Dermatol Ther. 2022;12(6):1289–1302. doi: 10.1007/s13555-022-00746-6.
   PubMed Web of Science ®Google Scholar
• Hjuler KF, Iversen L, Rasmussen MK, et al. Localization of treatment-resistant areas in patients with psoriasis on biologics. Br J Dermatol. 2019;181(2):332–337. doi: 10.1111/bjd.17689.
   PubMed Web of Science ®Google Scholar
• Piaserico S, Riedl E, Pavlovsky L, et al. Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the Observational Psoriasis Study of Health Outcomes (PSoHO). Front Med. 2023;10:1185523. doi: 10.3389/fmed.2023.1185523.
   Web of Science ®Google Scholar
• da Silva N, Augustin M, Langenbruch A, et al. Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: results from a large-scale survey in routine care. Eur J Dermatol. 2020;30(3):267–278. doi: 10.1684/ejd.2020.3768.
   PubMed Web of Science ®Google Scholar
• Strober B, Duffin KC, Lebwohl M, et al. Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas Psoriasis Registry. J Dermatolog Treat. 2024;35(1):2287401.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Barker J, Conrad C, et al. Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: results from the EMBRACE randomized trial. J Eur Acad Dermatol Venereol. 2023;37(2):348–355. doi: 10.1111/jdv.18689.
   PubMed Web of Science ®Google Scholar
• Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi Consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82(1):117–122. doi: 10.1016/j.jaad.2019.08.026.
   PubMed Web of Science ®Google Scholar
• Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China (2023 edition). Zhonghua Pifuke Zazhi. 2023;56(7):573–625.
   Google Scholar